Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in Stock

CFO Aaron Freidin sold 4,100 shares of GRAIL, Inc. stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $93.34, for a total transaction of $382,694.00. Following the transaction, the chief financial officer owned 248,983 shares in the company, valued at $23,240,073.22.

GRAIL, Inc. (NASDAQ:GRAL) opened at $126.89 on Friday. The company has a market capitalization of $5.67 billion, a P/E ratio of -13.01 and a beta of 3.25. GRAIL, Inc. has a 12 month low of $41.50 and a 12 month high of $127.67. The firm has a fifty day simple moving average of $78.42 and a 200-day simple moving average of $65.68.

GRAIL (NASDAQ:GRAL) last released its earnings results on Wednesday, August 5th. The company reported ($2.56) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.66) by $0.10. GRAIL had a negative return on equity of 15.88% and a negative net margin of 236.95%.The firm had revenue of $44.69 million for the quarter, compared to the consensus estimate of $42.39 million. Equities analysts forecast that GRAIL, Inc. will post -10.41 EPS for the current year.

FDA advisers recommended approval of Galleri after supporting its safety and narrowly endorsing its efficacy. A final FDA ruling is expected in the coming months; approval could expand insurance coverage, market access and adoption of GRAIL’s primary product.

The regulatory catalyst has driven a substantial weekly rally and helped GRAL reach a new 52-week high, as investors price in the potential commercial impact of FDA approval.

Analyst sentiment remains cautious following the rally. Mizuho raised its price target to $100 from $65 but maintained a neutral rating, while RBC Capital reiterated its hold rating. These targets remain below recent trading levels, suggesting analysts view much of the FDA optimism as already reflected in the valuation.

The panel’s narrow efficacy endorsement leaves regulatory and adoption risks unresolved. Galleri’s commercial opportunity depends on final FDA approval, physician and insurer acceptance, and evidence that the test improves patient outcomes.

Insider selling may weigh modestly on sentiment: CEO Joshua Ofman sold 61,452 shares and CFO Aaron Freidin sold 4,100 shares under pre-arranged Rule 10b5-1 plans. The transactions are less concerning than discretionary sales but can add pressure after the sharp advance.

Several large investors have recently made changes to their positions in GRAL. State Street Corp boosted its holdings in GRAIL by 26.1% during the second quarter. State Street Corp now owns 2,385,514 shares of the company's stock worth $162,859,000 after buying an additional 493,621 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in GRAIL by 26.3% in the second quarter. The Manufacturers Life Insurance Company now owns 21,597 shares of ...